{"protocolSection": {"identificationModule": {"nctId": "NCT01871558", "orgStudyIdInfo": {"id": "CLAF237AFR07"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin", "officialTitle": "Randomized, Open-label, SU-controlled Study of 24-week Duration to Compare Metformin/Vildagliptin + Basal Insulin Versus Metformin/SU + Basal Insulin in T2DM Patients Starting Basal Insulin After Failing Metformin/SU", "acronym": "ADDONIS"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-06"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-06-04", "studyFirstSubmitQcDate": "2013-06-04", "studyFirstPostDateStruct": {"date": "2013-06-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-02-22", "resultsFirstSubmitQcDate": "2016-02-22", "resultsFirstPostDateStruct": {"date": "2016-03-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-22", "lastUpdatePostDateStruct": {"date": "2016-04-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.", "detailedDescription": "This study, conducted in T2DM patients failing a dual therapy with metformin/SU in whom the decision to start basal insulin has been taken, will compare vildagliptin+metformin versus the previously used SU+met combination (regimen kept unchanged) in association with basal insulin, up-titrated as per usual algorithms primarily based on FPG to obtain a similar improvement in glycemic control in both arms, on the incidence of hypoglycemic episodes over 24 weeks."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus (T2DM)"], "keywords": ["type 2 diabetes", "basal insulin", "vildagliptin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 42, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SU+metformin + Basal Insulin", "type": "ACTIVE_COMPARATOR", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG", "interventionNames": ["Drug: Metformin", "Drug: sulfonylurea (SU)", "Drug: Basal Insulin"]}, {"label": "Metformin/vildagliptin + Basal Insulin", "type": "EXPERIMENTAL", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG", "interventionNames": ["Drug: Vildagliptin", "Drug: Metformin", "Drug: Basal Insulin"]}], "interventions": [{"type": "DRUG", "name": "Vildagliptin", "description": "50 mg b.i.d", "armGroupLabels": ["Metformin/vildagliptin + Basal Insulin"], "otherNames": ["Galvus"]}, {"type": "DRUG", "name": "Metformin", "description": "metformin is to be kept unchanged", "armGroupLabels": ["Metformin/vildagliptin + Basal Insulin", "SU+metformin + Basal Insulin"]}, {"type": "DRUG", "name": "sulfonylurea (SU)", "armGroupLabels": ["SU+metformin + Basal Insulin"]}, {"type": "DRUG", "name": "Basal Insulin", "armGroupLabels": ["Metformin/vildagliptin + Basal Insulin", "SU+metformin + Basal Insulin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms", "timeFrame": "24 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Patients Reaching Their Glycemic Target Without Hypoglycemic Events", "description": "Glycemic target is defined as Glycated hemoglobin(HbA1c) \u2264 7%", "timeFrame": "24 weeks"}, {"measure": "Change From Baseline in HbA1c to Week 24 in Both Treatment Arms", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Body Weight in Both Treatment Arms", "timeFrame": "Baseline, Week 24"}, {"measure": "Mean Daily Insulin Dose at Week 24", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients With Severe and Confirmed Hypoglycemic Events", "description": "Severe hypoglycemic events (and number of events) , defined as events requiring assistance of a third party, and with confirmed hypoglycemic events (and number of events) defined as events with concomitant self monitoring of blood glucose (SMBG) \\< 70 mg/dL", "timeFrame": "24 weeks"}, {"measure": "Percent of Participants That Reach Therapeutic Goal (HbA1c \u2264 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation \u22653% Compared to Baseline)", "description": "HbA1c \\<= 7% without any hypoglycaemic episode (symptomatic or not) and without any weight gain", "timeFrame": "week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* T2DM patients inadequately controlled with metformin+ SU combination therapy at max tolerated doses and in whom the decision to start basal insulin has been taken\n* with stable metformin+ SU combination therapy for at least 12 weeks prior to randomization\n* with a glycemic target of HbA1c \\<= 7%\n* with HbA1c at inclusion \\>7% and \\<=9%\n* Patients willing and able to start basal insulin and perform appropriate self monitoring of blood glucose (SMBG)\n\nExclusion Criteria:\n\n* contraindication for either SUs, metformin or insulin and history of hypersensitivity to vildagliptin\n* acute or chronic diseases that interfere with efficacy/safety results of this trial or put patient at risk\n\nOther protocol defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Antibes", "zip": "06600", "country": "France", "geoPoint": {"lat": 43.56241, "lon": 7.12777}}, {"facility": "Novartis Investigative Site", "city": "Auxerre", "zip": "89000", "country": "France", "geoPoint": {"lat": 47.8, "lon": 3.56667}}, {"facility": "Novartis Investigative Site", "city": "Bar le Duc", "zip": "55012", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 5.16667}}, {"facility": "Novartis Investigative Site", "city": "Bondy", "zip": "93143", "country": "France", "geoPoint": {"lat": 48.9018, "lon": 2.48931}}, {"facility": "Novartis Investigative Site", "city": "Brest", "zip": "29200", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Novartis Investigative Site", "city": "Caen", "zip": "14000", "country": "France", "geoPoint": {"lat": 49.18585, "lon": -0.35912}}, {"facility": "Novartis Investigative Site", "city": "Corbeil Essonnes", "zip": "91100", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "Novartis Investigative Site", "city": "Fleury sur Orne", "zip": "14123", "country": "France", "geoPoint": {"lat": 49.14851, "lon": -0.37508}}, {"facility": "Novartis Investigative Site", "city": "Maisons Laffitte", "zip": "78600", "country": "France", "geoPoint": {"lat": 48.95264, "lon": 2.14521}}, {"facility": "Novartis Investigative Site", "city": "Menton", "zip": "06500", "country": "France", "geoPoint": {"lat": 43.77649, "lon": 7.50435}}, {"facility": "Novartis Investigative Site", "city": "Montpellier", "zip": "34090", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novartis Investigative Site", "city": "Paris", "zip": "75010", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Rennes", "zip": "35203", "country": "France", "geoPoint": {"lat": 48.11198, "lon": -1.67429}}, {"facility": "Novartis Investigative Site", "city": "Saint Nazaire", "zip": "44600", "country": "France", "geoPoint": {"lat": 47.28333, "lon": -2.2}}, {"facility": "Novartis Investigative Site", "city": "Sanary Sur Mer", "zip": "83110", "country": "France", "geoPoint": {"lat": 43.11783, "lon": 5.80007}}, {"facility": "Novartis Investigative Site", "city": "Strsbourg", "zip": "67000", "country": "France"}, {"facility": "Novartis Investigative Site", "city": "Toulouse", "zip": "31300", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Novartis Investigative Site", "city": "Valence", "zip": "26000", "country": "France", "geoPoint": {"lat": 44.93333, "lon": 4.9}}, {"facility": "Novartis Investigative Site", "city": "Valenciennes", "zip": "59300", "country": "France", "geoPoint": {"lat": 50.35, "lon": 3.53333}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "FG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "21"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Other reason", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "antidiabetic drug prematurely stopped", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "BG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "42"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.6", "spread": "12.52"}, {"groupId": "BG001", "value": "66.8", "spread": "7.80"}, {"groupId": "BG002", "value": "63.7", "spread": "10.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "24"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms", "populationDescription": "safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.2"}, {"groupId": "OG001", "value": "45.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.139", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Reaching Their Glycemic Target Without Hypoglycemic Events", "description": "Glycemic target is defined as Glycated hemoglobin(HbA1c) \u2264 7%", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.4"}, {"groupId": "OG001", "value": "47.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c to Week 24 in Both Treatment Arms", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "HbA1c percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.2", "spread": "0.56"}, {"groupId": "OG001", "value": "8.2", "spread": "0.42"}]}]}, {"title": "week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2", "spread": "0.71"}, {"groupId": "OG001", "value": "7.4", "spread": "0.89"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight in Both Treatment Arms", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "2.51"}, {"groupId": "OG001", "value": "1.4", "spread": "2.61"}]}]}]}, {"type": "SECONDARY", "title": "Mean Daily Insulin Dose at Week 24", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "(U/d)", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.0", "spread": "23.08"}, {"groupId": "OG001", "value": "19.8", "spread": "13.83"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Severe and Confirmed Hypoglycemic Events", "description": "Severe hypoglycemic events (and number of events) , defined as events requiring assistance of a third party, and with confirmed hypoglycemic events (and number of events) defined as events with concomitant self monitoring of blood glucose (SMBG) \\< 70 mg/dL", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Participants That Reach Therapeutic Goal (HbA1c \u2264 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation \u22653% Compared to Baseline)", "description": "HbA1c \\<= 7% without any hypoglycaemic episode (symptomatic or not) and without any weight gain", "populationDescription": "ITT population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "week 24", "groups": [{"id": "OG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}, {"id": "OG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.8"}, {"groupId": "OG001", "value": "21.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Metformin/Vildagliptin + Basal Insulin", "description": "Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG", "seriousNumAffected": 0, "seriousNumAtRisk": 21, "otherNumAffected": 4, "otherNumAtRisk": 21}, {"id": "EG001", "title": "SU+Metformin + Basal Insulin", "description": "Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG", "seriousNumAffected": 0, "seriousNumAtRisk": 21, "otherNumAffected": 10, "otherNumAtRisk": 21}], "otherEvents": [{"term": "Conjunctival haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Parkinson's disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Cataract operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Clinical Disclosure Office", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077597", "term": "Vildagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "100%", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}